Patents Issued in July 27, 2017
-
Publication number: 20170209480Abstract: Esterified polysaccharide osmotics are provided as are the use of same, a process for synthesis of same, and compositions containing same.Type: ApplicationFiled: April 7, 2017Publication date: July 27, 2017Inventors: Dominik Fenn, Thomas Fichert, Thomas Schweitzer, Ingo Bichlmaier
-
Publication number: 20170209481Abstract: The present invention is directed to methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio.Type: ApplicationFiled: December 16, 2016Publication date: July 27, 2017Inventors: Paul Mansky, Detlef Albrecht, Michael Burdick, Han-Ting Chang, Dominique Charmot, Eric Connor, Sherin Halfon, I-Zu Huang, Mingjun Liu, Werner Strüver
-
Publication number: 20170209482Abstract: Dendrimers comprising N-acyl urea terminal moieties are described herein. The dendrimers can be used, for example, in the treatment of arthritis.Type: ApplicationFiled: March 13, 2017Publication date: July 27, 2017Inventors: Luis Z. Avila, Robert J. Miller, Lauren Elizabeth Young, Rajesh Vasant Kamath
-
Publication number: 20170209483Abstract: A polymeric metal sequestrant providing antibiotic activity is provided. The polymeric metal sequestrant comprises a polyamine polymer covalently coupled to a chelator, wherein the chelator has a benzene ring with more than one hydroxyl group at any position that is free. The polymeric metal sequestrant is effective in inhibiting and preventing bacterial infections and displays synergistic effects in combination with traditional antibiotics.Type: ApplicationFiled: April 7, 2017Publication date: July 27, 2017Inventors: Cory Berkland, Mario Rivera, Kate Eshelman, Jian Qian, Nashwa El-Gendy
-
Publication number: 20170209484Abstract: The present disclosure provides silicone-based biophotonic compositions and methods useful in phototherapy. In particular, the silicone-based biophotonic compositions of the present disclosure include a silicone phase and a surfactant phase, wherein the surfactant phase comprises at least one chromophore solubilized in a surfactant. The silicone-based biophotonic compositions and the methods of the present disclosure are useful for promoting wound healing and scarring, as well as various other skin disorders.Type: ApplicationFiled: June 9, 2015Publication date: July 27, 2017Inventors: Remigio Piergallini, Nikolaos Loupis, Joanna Jaworska, Emmanuelle Devemy, Éric DesRosiers, Abdellatif Chenite
-
Publication number: 20170209485Abstract: A topical application of nitric oxide may be provided by two separate containers, each containing an active component media to produce nitric oxide when combined. For example, a nitrite component media may be contained in one dispenser and an acidified component media may be contained in another dispenser. Each dispenser may dispense the respective component media as a foam. The resultant foams are combined to initiate the production of nitric oxide and the mixture of foams is applied topically to treat various skin disorders or wounds.Type: ApplicationFiled: January 25, 2017Publication date: July 27, 2017Inventors: C. Michael Miller, Gordon K. Hill, A. John Pate, David A. Bell
-
Publication number: 20170209486Abstract: A health-care preparation simultaneously with magnesium supplement and antioxidant functions and a preparation method thereof are disclosed. The health-care preparation comprises a main active ingredient of magnesium agent and an excipient. The magnesium agent is MgH2 micro-nano powder, and the excipient is a commonly used dietary supplement auxiliary material. Compared with the existing magnesium-supplementing preparation, the health-care preparation can simultaneously supplement magnesium which is the essential trace element in human body, and hydrogen which can neutralize oxygen free radicals. The present invention has the following advantages: it is convenient for storage and taking, and has a high conversion and absorption efficiency, a low cost, and no toxic side effects.Type: ApplicationFiled: April 6, 2017Publication date: July 27, 2017Inventors: Guangyin Yuan, Jia Pei, Wenjiang Ding
-
Publication number: 20170209487Abstract: An effervescent chewable dosage form that comprises a pH neutralization agent, an acid, and an effervescent agent. The chewable dosage form can also further comprise simethicone, a sweetener, and a lubricant. The pH neutralization agent can be calcium carbonate, the acid can be citric acid and the effervescent agent can be sodium bicarbonate.Type: ApplicationFiled: April 10, 2017Publication date: July 27, 2017Inventors: Mark Edward Stella, John Richard Entwisle, Jason William Newlon, Christine Louis Naykki
-
Publication number: 20170209488Abstract: The present invention relates to methods for treating neuromuscular junction-related diseases. In particular, the present invention relates to a method of treating a neuromuscular junction-related disease in a subject in need thereof comprising ad ministering the subject with a therapeutically effective amount of at least one inhibitor of glycogen synthase kinase 3 (GSK3).Type: ApplicationFiled: July 16, 2015Publication date: July 27, 2017Inventors: Laure Strochlic, Julien Messeant, Perrine Delers, Alexandre Dobbertin, Claire Legay
-
Publication number: 20170209489Abstract: The present invention relates to the discovery that a hydrated salt form of zinc exhibits enhanced activity in reducing the acidity of gastric juice in a subject in need when compared to typical zinc salts. According to the invention, a zinc salt hydrate may be used alone or in combination with an additional zinc salt hydrate. Optionally these zinc salt hydrate(s) may be combined with at least one additional zinc salt. The zinc salt hydrate may be further combined with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent or additional therapeutic agents for providing fast action with optional long duration effect in reducing gastric acid secretion. In addition, the proposed methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.Type: ApplicationFiled: March 31, 2015Publication date: July 27, 2017Inventor: John P. Geibel
-
Publication number: 20170209490Abstract: A nanoparticle composition for treating onychomycosis includes spherical-shaped nanoparticles having a particle size and a particle size distribution and coral-shaped nanoparticles having a particle size and a particle size distribution mixed within a penetrating solvent configured to deliver the nanoparticles to target area of a nail and/or surrounding tissue. The nanoparticle composition can be mixed with a carrier to provide or augment application of the nanoparticle composition to a target area. The penetrating solvent can deliver the nanoparticles to an infected area within the nail and/or at the bed of the nail so as to kill or deactivate the fungal microbes causing the onychomycosis.Type: ApplicationFiled: January 25, 2017Publication date: July 27, 2017Inventor: William H. Niedermeyer
-
Publication number: 20170209491Abstract: Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles. This material has applications in biomedicine due to its biodegradability and bioactivity; it also promotes cell adhesion and osteogeneration. In dentistry, it may be used in toothpastes, mouthwashes, chewing gums, gels and fluoride varnishes as a remineralising agent of dentine and enamel. It is based on two solutions formed by calcium chloride and sodium citrate on the one hand, and by sodium monohydrogenophosphate and sodium carbonate with a fluoride compound on the other, which are mixed at room temperature. The process is eco-efficient and eco-friendly, as it does not leave any acid residue; it consists of a single stage and it is the first time that an amorphous calcium phosphate coated with citrate and doped with fluoride, which enhances its remineralising action, is obtained.Type: ApplicationFiled: July 21, 2015Publication date: July 27, 2017Applicants: Consejo Superior De Investigaciones Científicas (C SIC), Consiglio Nazionale Delle RicercheInventors: Jose Manuel Delgado Lopez, Jaime Gomez Morales, Raquel Fernandez Penas, Michele Iafisco, Anna Tampieri, Silvia Panseri
-
Publication number: 20170209492Abstract: This disclosure provides, for instance subset-optimized CART cells and related methods. For instance, the disclosure describes methods and compositions of CD4? and CD8? T cells that express CARs containing specific combinations of intracellular signaling domains can be used to increase persistence and anti-tumor activity of the infused CAR-expressing T cells for treating a subject having a disease, e.g., a cancer.Type: ApplicationFiled: July 31, 2015Publication date: July 27, 2017Applicants: NOVARTIS AG, The Trustees of the University of PennsylvaniaInventors: Carl H. June, Sonia Guedan Carrio, Avery D. Posey, John Scholler
-
Publication number: 20170209493Abstract: The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.Type: ApplicationFiled: February 12, 2016Publication date: July 27, 2017Applicants: ABT Holding Company, Katholieke Universiteit LeuvenInventors: Aernout LUTTUN, Robert J. DEANS
-
Publication number: 20170209494Abstract: The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.Type: ApplicationFiled: February 10, 2017Publication date: July 27, 2017Applicant: University of RochesterInventors: Steven GOLDMAN, Fraser J. SIM
-
Publication number: 20170209495Abstract: The present invention provides muscle-derived progenitor cells (MDCs) that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction into a site of soft tissue. Also provided are methods of isolating MDCs. The invention further provides methods of using compositions comprising MDCs for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to uses of MDCs for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle.Type: ApplicationFiled: November 9, 2016Publication date: July 27, 2017Inventors: Thomas Payne, Ronald Jankowski, Ryan Pruchnic, Michael B. Chancellor
-
Publication number: 20170209496Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.Type: ApplicationFiled: March 20, 2017Publication date: July 27, 2017Applicants: TiGenix, S.A.U., Universidad Autónoma de MadridInventors: María Gema FERNÁNDEZ MIGUEL, Manuel Ángel GONZÁLEZ DE LA PEÑA, Rosa Ana GARCÍA CASTRO, Mariano GARCÍA ARRANZ, Damián GARCÍA OLMO
-
Publication number: 20170209497Abstract: The present disclosure provides compositions including a human placental extract and biodegradable microparticles, sustained release angiogenesis-modulating compositions, compositions and methods for releasing a placental extract to a target over a period of time, and methods for inducing and/or modulating angiogenesis and identifying modulators of angiogenesis. The present disclosure also provides methods of making a composition, including a placental extract that can induce and/or modulate angiogenesis.Type: ApplicationFiled: May 7, 2015Publication date: July 27, 2017Inventors: PETER S. MCFETRIDGE, MARC C. MOORE
-
Publication number: 20170209498Abstract: The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including novel immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and/or AMP cells.Type: ApplicationFiled: April 6, 2017Publication date: July 27, 2017Applicant: Noveome Biotherapeutics, Inc,Inventors: Larry R. Brown, George L. Sing, Howard C. Wessel
-
Publication number: 20170209499Abstract: This invention provides pharmaceutical and cosmeceutical compositions, including anti-skin cancer compositions, N containing propolis and cyclodextrin, and compositions comprising one or more compounds present in propolis, including compositions comprising one or more compounds present as an inclusion complex with cyclodextrin. Methods of using such compounds and compositions, in particular in the treatment or prevention of skin cancers and skin disorders, and in enhancing skin health, are also provided.Type: ApplicationFiled: July 17, 2015Publication date: July 27, 2017Applicant: Manuka Health New Zealand LimitedInventors: Amanda Jan SUDDES, Owen John CATCHPOLE
-
Publication number: 20170209500Abstract: The present invention provides a composition comprising honey, a preservative and an aqueous carrier, wherein the honey is present in an amount in the range of from 2 to 50% w/w. Uses of the compositions of the invention for the management, treatment or prevention of a respiratory, ophthalmic, ear or vaginal condition in a subject, and for wound management are also described.Type: ApplicationFiled: July 20, 2015Publication date: July 27, 2017Inventor: Anthony Peter MOLONEY
-
Publication number: 20170209501Abstract: Described are recombinant Escherichia coli Nissle 1917 (“EcN”) cells transformed with genes that express proteins or polypeptides involved in omega 3 fatty acid biosynthesis. The recombinant EcN cells produce eicosapentaenoic acid (EPA) and/or docosahexaenoic acids (DHA). Associated compositions, methods and uses of the recombinant EcN cells are also provided.Type: ApplicationFiled: January 18, 2017Publication date: July 27, 2017Inventors: Mitra Amiri-Jami, Mansel W. Griffiths
-
Publication number: 20170209502Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: ApplicationFiled: March 28, 2017Publication date: July 27, 2017Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Publication number: 20170209503Abstract: The present invention relates a process of production of beadlets comprising probiotic compounds in a matrix comprising at least one starch and/or starch derivative, to such beadlets and to the use of such specific beadlets in food (for humans and animals) as well as in premixes.Type: ApplicationFiled: April 6, 2017Publication date: July 27, 2017Inventors: Elger FUNDA, Karin LEUTHARDT
-
Publication number: 20170209504Abstract: Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.Type: ApplicationFiled: September 6, 2016Publication date: July 27, 2017Applicants: Research Institute at Nationwide Children's Hospital, Ohio State Innovation FoundationInventors: Steven D. Goodman, Lauren O. Bakaletz, Gail Besner, Michael Bailey
-
Publication number: 20170209505Abstract: The present invention is directed to a personal care composition comprising: a hair restorative blend comprising a chalconoid, an Epilobium extract, a Laminaria extract, and cosmetically acceptable carrier.Type: ApplicationFiled: January 12, 2017Publication date: July 27, 2017Inventors: Alison Pawlus, Geoffrey Hawkins
-
Publication number: 20170209506Abstract: The present invention is directed to a method for treating the appearance of thinning hair of a human comprising the steps of; cleaning the hair with a shampoo composition; rinsing said shampoo from said hair; and applying a hair restorative blend to the scalp of said human, said hair restorative blend comprising; a chalconoid, an Epilobium extract, a Laminaria extract and a cosmetically acceptable carrier.Type: ApplicationFiled: January 12, 2017Publication date: July 27, 2017Inventors: Alison Pawlus, Geoffrey Hawkins
-
Publication number: 20170209507Abstract: Present invention relates to an allergy-inhibiting sea grape extract, its preparation method and thereof. The preparation method includes following steps: the sea grape is blended in distilled water in the weight ratio of 1:1˜20, mix thoroughly, stir at 20-100° C. for 30˜120 minutes. The fluid obtained after the first filtration is the sea grape extract. The sea grape extract can be subjected to the second filtration by using EW, PW and DK membranes and freeze-dried to give a refined sea grape extract. The invention exhibits superior allergy-inhibiting effect; moreover, the prepared extract does not cause allergy and can be used in cosmetics and food.Type: ApplicationFiled: January 21, 2016Publication date: July 27, 2017Inventors: Yu-Lin HUANG, Huey-Min LAI, Tsung-Han LEE, Wei-Yung HSIEH, Xiu-Ci SHEN, Tseng-Peng LI
-
Publication number: 20170209508Abstract: The present invention relates to the technical field of health-care food, especially relates to a traditional Chinese medicine composition for relieving chronic pain and preparation method and use thereof. The traditional Chinese medicine composition includes cinnamon bark oil and nutmeg oil. The traditional Chinese medicine composition of the present invention can effectively relieve chronic pain, and the effect of the composition is superior to single agent, and cinnamon bark oil and nutmeg oil can be used pharmaceutically and bromatologically and do not have side effects.Type: ApplicationFiled: January 17, 2017Publication date: July 27, 2017Applicant: INFINITUS (CHINA) COMPANY LTD.Inventors: Renhuai CONG, Fangli MA, Chung Wah MA
-
Publication number: 20170209509Abstract: The present invention provides an agent for suppressing the number of intestinal bacteria, which contains an extract and/or crushed product of a plant of the genus Salacia, wherein the intestinal bacterium is at least one which is selected from the group consisting of the families Lachnospiraceae, Ruminococcaceae, Fusobacteriaceae, and Desulfovibrionaceae.Type: ApplicationFiled: January 25, 2017Publication date: July 27, 2017Applicant: FUJIFILM CorporationInventors: Yuriko ODA, Fumitaka UEDA
-
Publication number: 20170209510Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.Type: ApplicationFiled: May 21, 2015Publication date: July 27, 2017Inventors: Jin Sook KIM, Junghyun KIM, Chan-Sik KIM, Eunjin SHON, Yun Mi LEE, Young Sook KIM, Sojin CHOI, Ik Soo LEE, Dong Ho JUNG, Bo-Jeong PYUN, Seung-Hyun JUNG
-
Publication number: 20170209511Abstract: The present invention relates to a food composition, and to a pharmaceutical composition, which exhibit anti-obesity effects by means of a thermogenesis produced by an activity of a UCP of fat cells, which exhibit anti-diabetes effects by means of an improved insulin resistance, increase muscle mass, and improve capacity for exercise. More particularly, the present invention relates to a novel use of a composition containing extracts of piper retrofractum, and to the food composition or pharmaceutical composition which exhibit anti-obesity effects by means of decreased body weight and body fat, exhibit anti-diabetes effects by means of ameliorated insulin resistance through the reduction of blood glucose and blood insulin, increase muscle mass by increasing an energy source being supplied to the muscles, and improve the capacity for exercise including increased endurance.Type: ApplicationFiled: February 15, 2017Publication date: July 27, 2017Applicants: CJ CHEILJEDANG CORP., INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Kyung-Jin KIM, Min-Sun KIM, Jae-Kwan HWANG
-
Publication number: 20170209512Abstract: Use of a composition comprising the administration of crushed leaves of green tea in the treatment of type I allergy. The composition may especially be enriched with substances extracted from green tea, preferably catechin or a derivative thereof. The veterinary treatment of type I allergy, as in the treatment of sweet itch, is especially envisaged. A preferred embodiment comprises a composition for use according to the present invention, as well as a veterinary pharmaceutical formulation comprising a composition according to the invention, and a veterinary pharmaceutical formulation comprising said composition.Type: ApplicationFiled: April 10, 2017Publication date: July 27, 2017Inventors: Edwin Johannus Tijhaar, Johnny Franciscus Cornelis Molenaar, Mary Rose Elzinga
-
Publication number: 20170209513Abstract: Blood Pressure Reduction with Dietary Supplements Abstract A daily dose of 6,000 mg of taurine, 1,000 mg of vitamin C, 150 mg of grape seed extract, 100 mg of vitamin B6, 2 mg of biotin, 2,000 IU of vitamin D3, and 87 mg of magnesium is shown to reduce blood pressure in hypertensive individuals byType: ApplicationFiled: April 6, 2017Publication date: July 27, 2017Inventors: William S. Sparks, Daryl L. De Luca, Denis R. De Luca, Mark Houston
-
Publication number: 20170209514Abstract: The present invention is directed to a novel use of bamboo on the promotion of bone length growth. More specifically, it is directed to a pharmaceutical composition, a food composition and/or an animal feed composition for promoting bone growth, comprising a bamboo as an effective ingredient. Further, it is also directed to a method for promoting bone growth, comprising administering to a subject in need thereof an effective amount of a bamboo. Since the composition of the present invention comprising bamboo as an effective ingredient is effective for promoting the growth of the growth plates and the long bones, it is effective for promoting the growth and the formation of skeletal frame in infants, children and teenagers during their growth period. In addition, the composition of the present invention is effective for the treatment of height growth solely or in combination with growth hormone therapies.Type: ApplicationFiled: April 6, 2017Publication date: July 27, 2017Inventors: Hohyun Kim, Sooyeon Kim, Ji Hoon Jeong
-
Publication number: 20170209515Abstract: Disclosed are a pharmaceutical composition and a health functional food for the prevention and treatment of diabetic peripheral neuropathy, comprising an herb extract of a mixture of 3.5:1 Dioscorea Rhizoma:Dioscorea nipponica (w/w). Having the ability to synergistically increase in vivo levels of nerve growth factor, compared to the extracts from the herbs alone or herb mixtures of other weight ratios, the mixed herb extract is effective for preventing the apoptosis of nerve cells and promoting nerve regeneration. Thus, it can be applied to pharmaceutical compositions and health functional foods preventive and curative of diabetic peripheral neuropathy.Type: ApplicationFiled: April 10, 2017Publication date: July 27, 2017Inventors: Soon-Hoe KIM, Mi-Won SON, Sang-Zin CHOI, Hye-Ju KIM, Ja-Young RYU, Sun-Yeou KIM
-
Publication number: 20170209516Abstract: A herbal composition for relieving symptoms of diabetic retinopathy includes 40 wt % of an ethanol extract of Astragalus membranaceus, 8 wt % of an ethanol extract of Angelica sinensis and 52 wt % of a water extract of Dendrobium officinale. A method for diabetic retinopathy by administrating the herbal composition to a subject in need is also provided.Type: ApplicationFiled: April 6, 2017Publication date: July 27, 2017Inventors: Shorong-Shii Liou, I-Min Liu, Kun-Yi Hong
-
Publication number: 20170209517Abstract: The present invention relates to Coix seed oil extracted from Semen Coicis, pharmaceutical preparations thereof, and the use thereof in the treatment of tumors. Specifically, the Coix seed oil contains 11 triglyceride ingredients in the following mass percentages: trilinolein 4.87-6.99%, 1-olein-2,3-dilinolein 13.00-18.69%, 1-palmitin-2,3-dilinolein 5.25-7.54%, 1,3-diolein-2-linolein 13.23-19.02%, 1-palmitin-2-linolein-3-olein 10.26-14.75%, 1,3-dipalmitin-2-linolein 2.28-3.28%, triolein 14.44-20.76% and 1-palmitin-2,3-diolein 8.06-11.58%, 1-olein-2-linolein-3-stearin 1.37-1.97%, 1,3-dipalmitin-2-olein 1.52-2.19% and 1,2-diolein-3-stearin 1.29-1.86%.Type: ApplicationFiled: July 17, 2015Publication date: July 27, 2017Applicant: ZHEJIANG KANGLAITE GROUP CO., LTD.Inventor: DAPENG LI
-
Publication number: 20170209518Abstract: The present invention relates to Coix seed oil extracted from Semen Coicis, pharmaceutical preparations thereof, and the use thereof in the treatment of tumors. Specifically, the Coix seed oil contains 5 diglyceride and 11 triglyceride ingredients in the following mass percentages: 1,3-diolein 0.40-0.58%, 1-linolein-3-olein 0.91-1.31%, 1,2-diolein 0.24-0.35%, 1-olein-2-linolein 0.66-0.95%, 1,2-dilinolein 0.33-0.47%, trilinolein 4.87-6.99%, 1-olein-2,3-dilinolein 13.00-18.69%, 1-palmitin-2,3-dilinolein 5.25-7.54%, 1,3-diolein-2-linolein 13.23-19.02%, 1-palmitin-2-linolein-3-olein 10.26-14.75%, 1,3-dipalmitin-2-linolein 2.28-3.28%, triolein 14.44-20.76%, 1-palmitin-2,3-diolein 8.06-11.58%, 1-olein-2-linolein-3-stearin 1.37-1.97%, 1,3-dipalmitin-2-olein 1.52-2.19% and 1,2-diolein-3-stearin 1.29-1.86%.Type: ApplicationFiled: July 17, 2015Publication date: July 27, 2017Applicant: ZHEJIANG KANGLAITE GROUP CO., LTD.Inventor: Dapeng LI
-
Publication number: 20170209519Abstract: A pharmaceutical composition for treating or alleviating autoimmune-related diseases is provided, including an extract of Amomum tsao-ko as an active ingredient and a pharmaceutically acceptable carrier, in which the extract comprises Vanillin, Tsaokoin, or the combination thereof.Type: ApplicationFiled: January 26, 2017Publication date: July 27, 2017Applicant: Industrial Technology Research InstituteInventors: Kuo-Kuei HUANG, I-Horng PAN, Meng-Nan LIN, Jir-Mehng LO, Jennline SHEU, Pei-Ru LIAU, Yi-Cheng CHENG
-
Publication number: 20170209520Abstract: Compositions, foods, and medicaments for enhancing memory and learning function and/or cognitive function are provided. Compositions, foods, and medicaments for improving brain function and particularly enhancing memory and learning function and/or cognitive function can be provided by including a peptide including an amino acid sequence set forth in any one of SEQ ID NOs 1 to 16 as an active ingredient.Type: ApplicationFiled: June 16, 2015Publication date: July 27, 2017Applicant: KIRIN KABUSHIKI KAISHAInventors: Yasuhisa ANO, Toshiko KUTSUKAKE
-
Publication number: 20170209521Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.Type: ApplicationFiled: December 7, 2016Publication date: July 27, 2017Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
-
Publication number: 20170209522Abstract: An object of the present invention is to provide an external use composition having a novel composition that has a superior effect promoting collagen production and is able to suppress, prevent or improve wrinkles and sagging of the skin with aging. The present invention relates to an external use composition for anti-aging, comprising (A) a lipopeptide represented by the following formula (1), or a pharmaceutically acceptable salt thereof: (wherein, R1 represents a saturated aliphatic group, or aliphatic group having a single unsaturated bond, having 9 to 19 carbon atoms, and m represents 0 or 1).Type: ApplicationFiled: June 30, 2015Publication date: July 27, 2017Inventors: Masatoshi Haga, Keiko Oyamada, Rumi Matsushita, Yuya Hayashi, Kyoko Nakajima, Yuko Kouda
-
Publication number: 20170209523Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.Type: ApplicationFiled: April 10, 2017Publication date: July 27, 2017Inventors: Gerold L. MOSHER, David W. MILES
-
Publication number: 20170209524Abstract: Provided herein are methods of suppressing viral nucleic acid, e.g. double-stranded (ds) DNA, genome release from or packaging of viruses having their nucleic acid genome packaged under stress in their capsid, and compositions useful for that purpose. The methods alter the ionic environment of the nucleic acid within the capsid and thereby prevent release of, and/or interfere with packaging of the viral genome.Type: ApplicationFiled: January 30, 2017Publication date: July 27, 2017Inventor: Alex Evilevitch
-
Publication number: 20170209525Abstract: Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.Type: ApplicationFiled: February 22, 2017Publication date: July 27, 2017Inventors: Andrea Leone-Bay, Richard A. Houghten, Joseph J. Guarneri, Grayson W. Stowell
-
Publication number: 20170209526Abstract: The inventors have identified how the assembly of the 5-HT2cR with another protein (phosphatase and tensin homologue; PTEN) controls cellular function, and have synthesized a new peptide that interrupts the 5-HT2cR:PTEN complex to result in enhanced 5-HT2cR function.Type: ApplicationFiled: March 6, 2017Publication date: July 27, 2017Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Kathryn Cunningham, Scott Gilbertson
-
Publication number: 20170209527Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: February 8, 2017Publication date: July 27, 2017Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20170209528Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of metabolic conditions. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: February 8, 2017Publication date: July 27, 2017Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20170209529Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.Type: ApplicationFiled: November 17, 2016Publication date: July 27, 2017Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.Inventors: Richard S. BLUMBERG, Timo RATH, Kristi BAKER, Adam MEZO, Zachary TAYLOR, Kevin MCDONNELL, Rosa Maria Silva Garcia GRENHA